BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences

February 4, 2026

BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

Buyers
BioSelective Capital Investments, Shayan Enterprises, LLC
Targets
BioDuro's Irvine drug product development and manufacturing operations (now Forma Life Sciences, Inc.)
Sellers
BioDuro, Advent International
Industry
Pharmaceuticals
Location
California, United States
Transaction Type
Divestiture

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.